Table of Contents Author Guidelines Submit a Manuscript
Advances in Medicine
Volume 2014, Article ID 464851, 14 pages
http://dx.doi.org/10.1155/2014/464851
Review Article

Percutaneous Septal Ablation in Hypertrophic Obstructive Cardiomyopathy: From Experiment to Standard of Care

Department of Cardiology, Heart and Diabetes Center North Rhine-Westphalia, University Hospital of the Ruhr University Bochum, Georgstraße 11, 32545 Bad Oeynhausen, Germany

Received 29 December 2013; Accepted 7 March 2014; Published 6 May 2014

Academic Editor: Jesus Peteiro

Copyright © 2014 Lothar Faber. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. D. Teare, “Asymmetrical hypertrophy of the heart in young adults,” British Heart Journal, vol. 20, no. 1, pp. 1–8, 1958. View at Google Scholar · View at Scopus
  2. E. Braunwald, C. T. Lambrew, S. D. Rockoff, J. Ross Jr., and A. G. Morrow, “Idiopathic hypertrophic subaortic stenosis, I: a description of the disease based upon an analysis of 64 patients,” Circulation, vol. 30, pp. 3–119, 1964. View at Google Scholar · View at Scopus
  3. B. J. Maron, “Hypertrophic cardiomyopathy: a systematic review,” Journal of the American Medical Association, vol. 287, no. 10, pp. 1308–1320, 2002. View at Google Scholar · View at Scopus
  4. P. Spirito, C. E. Seidman, W. J. McKenna, and B. J. Maron, “The management of hypertrophic cardiomyopathy,” The New England Journal of Medicine, vol. 336, no. 11, pp. 775–785, 1997. View at Publisher · View at Google Scholar · View at Scopus
  5. E. D. Wigle, H. Rakowski, B. P. Kimball, and W. G. Williams, “Hypertrophic cardiomyopathy: clinical spectrum and treatment,” Circulation, vol. 92, no. 7, pp. 1680–1692, 1995. View at Google Scholar · View at Scopus
  6. B. J. Maron, W. J. McKenna, G. K. Danielson et al., “American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 42, pp. 1687–1713, 2003. View at Publisher · View at Google Scholar
  7. B. J. Maron, I. Olivotto, P. Spirito et al., “Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population,” Circulation, vol. 102, no. 8, pp. 858–864, 2000. View at Google Scholar · View at Scopus
  8. B. J. Gersh, B. J. Maron, R. O. Bonow et al., “2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of cardiology foundation/American heart association task force on practice guidelines,” Circulation, vol. 124, no. 24, pp. 2761–2796, 2011. View at Publisher · View at Google Scholar · View at Scopus
  9. C. Prinz, M. Farr, D. Hering, D. Horstkotte, and L. Faber, “The diagnosis and treatment of hypertrophic cardiomyopathy,” Deutsches Arzteblatt International, vol. 108, no. 13, pp. 209–215, 2011. View at Publisher · View at Google Scholar · View at Scopus
  10. C. Rapezzi, E. Arbustini, A. L. Caforio et al., “Diagnostic work-up in cardiomyopathies: bridging the gap between clinical phenotypes and final diagnosis: a position statement from the ESC Working Group on myocardial and Pericardial Diseases,” European Heart Journal, vol. 34, pp. 1448–1458, 2013. View at Google Scholar
  11. H. G. Klues, A. Schiffers, and B. J. Maron, “Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients,” Journal of the American College of Cardiology, vol. 26, no. 7, pp. 1699–1708, 1995. View at Publisher · View at Google Scholar · View at Scopus
  12. K. M. Harris, P. Spirito, M. S. Maron et al., “Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 54, no. 3, pp. 191–200, 2009. View at Publisher · View at Google Scholar
  13. H. G. Klues, B. J. Maron, A. L. Dollar, and W. C. Roberts, “Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy,” Circulation, vol. 85, no. 5, pp. 1651–1660, 1992. View at Google Scholar · View at Scopus
  14. M. S. Maron, I. Olivotto, C. Harrigan et al., “Mitral valve abnormalities identified by cardiovascular magnetic resonance represent a primary phenotypic expression of hypertrophic cardiomyopathy,” Circulation, vol. 124, no. 1, pp. 40–47, 2011. View at Publisher · View at Google Scholar · View at Scopus
  15. E. Schwammenthal, S. Nakatani, S. He et al., “Mechanism of mitral regurgitation in hypertrophic cardiomyopathy: mismatch of posterior to anterior leaflet length and mobility,” Circulation, vol. 98, no. 9, pp. 856–865, 1998. View at Google Scholar · View at Scopus
  16. M. S. Maron, A. G. Zenovich, S. A. Casey et al., “Significance and relation between magnitude of left ventricular hypertrophy and heart failure symptoms in hypertrophic cardiomyopathy,” American Journal of Cardiology, vol. 95, no. 11, pp. 1329–1333, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. P. Spirito, P. Bellone, K. M. Harris, P. Bernabò, P. Bruzzi, and B. J. Maron, “Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy,” The New England Journal of Medicine, vol. 342, no. 24, pp. 1778–1785, 2000. View at Publisher · View at Google Scholar · View at Scopus
  18. I. Olivotto, M. S. Maron, C. Autore et al., “Assessment and significance of left ventricular mass by cardiovascular magnetic resonance in hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 52, no. 7, pp. 559–566, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. M. S. Maron, I. Olivotto, A. G. Zenovich et al., “Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction,” Circulation, vol. 114, no. 21, pp. 2232–2239, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. P. M. Elliott, J. Poloniecki, S. Dickie et al., “Sudden death in hypertrophic cardiomyopathy: identification of high risk patients,” Journal of the American College of Cardiology, vol. 36, no. 7, pp. 2212–2218, 2000. View at Publisher · View at Google Scholar · View at Scopus
  21. B. J. Maron, “Contemporary insights and strategies for risk stratification and prevention of sudden death in hypertrophic cardiomyopathy,” Circulation, vol. 121, no. 3, pp. 445–456, 2010. View at Publisher · View at Google Scholar · View at Scopus
  22. M. S. Maron, B. J. Maron, C. Harrigan et al., “Hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance,” Journal of the American College of Cardiology, vol. 54, no. 3, pp. 220–228, 2009. View at Publisher · View at Google Scholar · View at Scopus
  23. C. Rickers, N. M. Wilke, M. Jerosch-Herold et al., “Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy,” Circulation, vol. 112, no. 6, pp. 855–861, 2005. View at Publisher · View at Google Scholar · View at Scopus
  24. J. C. C. Moon, N. G. Fisher, W. J. McKenna, and D. J. Pennell, “Detection of apical hypertrophic cardiomyopathy by cardiovascular magnetic resonance in patients with non-diagnostic echocardiography,” Heart, vol. 90, no. 6, pp. 645–649, 2004. View at Google Scholar · View at Scopus
  25. P. M. Elliott, J. R. Gimeno Blanes, N. G. Mahon, J. D. Poloniecki, and W. J. McKenna, “Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy,” The Lancet, vol. 357, no. 9254, pp. 420–424, 2001. View at Publisher · View at Google Scholar · View at Scopus
  26. B. J. Maron, K. P. Carney, H. M. Lever et al., “Relationship of race to sudden cardiac death in competitive athletes with hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 41, no. 6, pp. 974–980, 2003. View at Publisher · View at Google Scholar · View at Scopus
  27. D. Corrado, C. Basso, M. Schiavon, and G. Thiene, “Screening for hypertrophic cardiomyopathy in young athletes,” The New England Journal of Medicine, vol. 339, no. 6, pp. 364–369, 1998. View at Publisher · View at Google Scholar · View at Scopus
  28. M. S. Maron, J. J. Finley, J. M. Bos et al., “Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy,” Circulation, vol. 118, no. 15, pp. 1541–1549, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. M. S. Maron, J. R. Lesser, and B. J. Maron, “Management implications of massive left ventricular hypertrophy in hypertrophic cardiomyopathy significantly underestimated by echocardiography but identified by cardiovascular magnetic resonance,” American Journal of Cardiology, vol. 105, no. 12, pp. 1842–1843, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. I. Olivotto, B. J. Maron, E. Appelbaum et al., “Spectrum and clinical significance of systolic function and myocardial fibrosis assessed by cardiovascular magnetic resonance in hypertrophic cardiomyopathy,” American Journal of Cardiology, vol. 106, no. 2, pp. 261–267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. J. B. Geske, P. Sorajja, R. A. Nishimura, and S. R. Ommen, “Evaluation of left ventricular filling pressures by Doppler echocardiography in patients with hypertrophic cardiomyopathy: correlation with direct left atrial pressure measurement at cardiac catheterization,” Circulation, vol. 116, no. 23, pp. 2702–2708, 2007. View at Publisher · View at Google Scholar · View at Scopus
  32. B. J. Maron, P. Spirito, K. J. Green, Y. E. Wesley, R. O. Bonow, and J. Arce, “Noninvasive assessment of left ventricular diastolic function by pulsed Doppler echocardiography in patients with hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 10, no. 4, pp. 733–742, 1987. View at Google Scholar · View at Scopus
  33. C. Autore, P. Bernabò, C. S. Barillà, P. Bruzzi, and P. Spirito, “The prognostic importance of left ventricular outflow obstruction in hypertrophic cardiomyopathy varies in relation to the severity of symptoms,” Journal of the American College of Cardiology, vol. 45, no. 7, pp. 1076–1080, 2005. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Elliott, J. Gimeno, M. Tomé, and W. McKenna, “Left ventricular outflow tract obstruction and sudden death in hypertrophic cardiomyopathy,” European Heart Journal, vol. 27, no. 24, p. 3073, 2006. View at Publisher · View at Google Scholar · View at Scopus
  35. M. S. Maron, I. Olivotto, S. Betocchi et al., “Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy,” The New England Journal of Medicine, vol. 348, no. 4, pp. 295–303, 2003. View at Publisher · View at Google Scholar · View at Scopus
  36. W. J. McKenna and J. E. Deanfield, “Hypertrophic cardiomyopathy: an important cause of sudden death,” Archives of Disease in Childhood, vol. 59, no. 10, pp. 971–975, 1984. View at Google Scholar · View at Scopus
  37. I. Olivotto, F. Cecchi, S. A. Casey, A. Dolara, J. H. Traverse, and B. J. Maron, “Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy,” Circulation, vol. 104, no. 21, pp. 2517–2524, 2001. View at Google Scholar · View at Scopus
  38. B. J. Maron, I. Olivotto, P. Bellone et al., “Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 39, no. 2, pp. 301–307, 2002. View at Publisher · View at Google Scholar · View at Scopus
  39. B. J. Maron, S. A. Casey, R. G. Hauser, and D. M. Aeppli, “Clinical course of hypertrophic cardiomyopathy with survival to advanced age,” Journal of the American College of Cardiology, vol. 42, no. 5, pp. 882–888, 2003. View at Publisher · View at Google Scholar · View at Scopus
  40. B. J. Maron, S. A. Casey, T. S. Haas, C. L. Kitner, R. F. Garberich, and J. R. Lesser, “Hypertrophic cardiomyopathy with longevity to 90 years or older,” American Journal of Cardiology, vol. 109, no. 9, pp. 1341–1347, 2012. View at Publisher · View at Google Scholar · View at Scopus
  41. C. J. McLeod, M. J. Ackerman, R. A. Nishimura, A. J. Tajik, B. J. Gersh, and S. R. Ommen, “Outcome of patients with hypertrophic cardiomyopathy and a normal electrocardiogram,” Journal of the American College of Cardiology, vol. 54, no. 3, pp. 229–233, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. R. Alcalai, J. G. Seidman, and C. E. Seidman, “Genetic basis of hypertrophic cardiomyopathy: from bench to the clinics,” Journal of Cardiovascular Electrophysiology, vol. 19, no. 1, pp. 104–110, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. A. P. Landstrom and M. J. Ackerman, “Mutation type is not clinically useful in predicting prognosis in hypertrophic cardiomyopathy,” Circulation, vol. 122, no. 23, pp. 2441–2449, 2010. View at Publisher · View at Google Scholar · View at Scopus
  44. P. Richard, P. Charron, L. Carrier et al., “Hypertrophic cardiomyopathy: distribution of disease genes, spectrum of mutations, and implications for a molecular diagnosis strategy,” Circulation, vol. 107, pp. 2227–2232, 2003. View at Publisher · View at Google Scholar
  45. J. G. Seidman and C. Seidman, “The genetic basis for cardiomyopathy: from mutation identification to mechanistic paradigms,” Cell, vol. 104, no. 4, pp. 557–567, 2001. View at Publisher · View at Google Scholar · View at Scopus
  46. B. J. Maron, J. G. Seidman, and C. E. Seidman, “Proposal for contemporary screening strategies in families with hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 44, no. 11, pp. 2125–2132, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Watkins, A. Rosenzweig, D.-S. Hwang et al., “Characteristics and prognostic implications of myosin missense mutations in familial hypertrophic cardiomyopathy,” The New England Journal of Medicine, vol. 326, no. 17, pp. 1108–1114, 1992. View at Google Scholar · View at Scopus
  48. J. M. Bos, J. A. Towbin, and M. J. Ackerman, “Diagnostic, prognostic, and therapeutic implications of genetic testing for hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 54, no. 3, pp. 201–209, 2009. View at Publisher · View at Google Scholar · View at Scopus
  49. B. J. Maron and W. C. Roberts, “Quantitative analysis of cardiac muscle cell disorganization in the ventricular septum of patients with hypertrophic cardiomyopathy,” Circulation, vol. 59, no. 4, pp. 689–706, 1979. View at Google Scholar · View at Scopus
  50. C. Y. Ho, B. López, O. R. Coelho-Filho et al., “Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy,” The New England Journal of Medicine, vol. 363, no. 6, pp. 552–563, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. B. J. Maron, J. K. Wolfson, S. E. Epstein, and W. C. Roberts, “Intramural ('small vessel') coronary artery disease in hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 8, no. 3, pp. 545–557, 1986. View at Google Scholar · View at Scopus
  52. J. Shirani, R. Pick, W. C. Roberts, and B. J. Maron, “Morphology and significance of the left ventricular collagen network in young patients with hypertrophic cardiomyopathy and sudden cardiac death,” Journal of the American College of Cardiology, vol. 35, no. 1, pp. 36–44, 2000. View at Publisher · View at Google Scholar · View at Scopus
  53. C. Prinz, M. Schwarz, I. Ilic et al., “Myocardial fibrosis severity on cardiac magnetic resonance imaging predicts sustained Arrhythmic events in hypertrophic cardiomyopathy,” Canadian Journal of Cardiology, vol. 29, no. 3, pp. 358–363, 2013. View at Google Scholar
  54. C. Prinz, F. van Buuren, L. Faber et al., “In patients with hypertrophic cardiomyopathy myocardial fibrosis is associated with both left ventricular and left atrial dysfunction,” Acta Cardiologica, vol. 67, no. 2, pp. 187–193, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. C. Prinz, F. van Buuren, L. Faber et al., “Myocardial fibrosis is associated with biventricular dysfunction in patients with hypertrophic cardiomyopathy,” Echocardiography, vol. 29, no. 4, pp. 438–444, 2012. View at Publisher · View at Google Scholar · View at Scopus
  56. C. Prinz, D. Hering, T. Bitter, D. Horstkotte, and L. Faber, “Left atrial size and left ventricular hypertrophy correlate with myocardial fibrosis in patients with hypertrophic cardiomyopathy,” Acta Cardiologica, vol. 66, no. 2, pp. 153–157, 2011. View at Publisher · View at Google Scholar · View at Scopus
  57. C. Prinz, M. Farr, K. T. Laser et al., “Determining the role of fibrosis in hypertrophic cardiomyopathy,” Expert Review of Cardiovascular Therapy, vol. 11, no. 4, pp. 495–504, 2013. View at Publisher · View at Google Scholar
  58. F. Cecchi, I. Olivotto, R. Gistri, R. Lorenzoni, G. Chiriatti, and P. G. Camici, “Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy,” The New England Journal of Medicine, vol. 349, no. 11, pp. 1027–1035, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. C. Basso, G. Thiene, D. Corrado, G. Buja, P. Melacini, and A. Nava, “Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia,” Human Pathology, vol. 31, no. 8, pp. 988–998, 2000. View at Publisher · View at Google Scholar · View at Scopus
  60. C. Prinz, L. Faber, D. Horstkotte et al., “Evaluation of left ventricular torsion in children with hypertrophic cardiomyopathy,” Cardiology in the Young, vol. 6, pp. 1–8, 2013. View at Google Scholar
  61. B. J. Maron and A. Pelliccia, “The heart of trained athletes: cardiac remodeling and the risks of sports, including sudden death,” Circulation, vol. 114, no. 15, pp. 1633–1644, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. D. Corrado, C. Basso, A. Pavei, P. Michieli, M. Schiavon, and G. Thiene, “Trends in sudden cardiovascular death in young competitive athletes after implementation of a preparticipation screening program,” Journal of the American Medical Association, vol. 296, no. 13, pp. 1593–1601, 2006. View at Publisher · View at Google Scholar · View at Scopus
  63. B. J. Maron, “The electrocardiogram as a diagnostic tool for hypertrophic cardiomyopathy: revisited,” Annals of Noninvasive Electrocardiology, vol. 6, no. 4, pp. 277–279, 2001. View at Google Scholar · View at Scopus
  64. J. A. Decker, J. W. Rossano, E. O. Smith et al., “Risk factors and mode of death in isolated hypertrophic cardiomyopathy in children,” Journal of the American College of Cardiology, vol. 54, no. 3, pp. 250–254, 2009. View at Publisher · View at Google Scholar · View at Scopus
  65. T. Germans, A. A. M. Wilde, P. A. Dijkmans et al., “Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations,” Journal of the American College of Cardiology, vol. 48, no. 12, pp. 2518–2523, 2006. View at Publisher · View at Google Scholar · View at Scopus
  66. T. Butz, F. van Buuren, K. P. Mellwig et al., “Two-dimensional strain analysis of the global and regional myocardial function for the differentiation of pathologic and physiologic left ventricular hypertrophy: a study in athletes and in patients with hypertrophic cardiomyopathy,” International Journal of Cardiovascular Imaging, vol. 27, no. 1, pp. 91–100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  67. R. Chan, B. J. Maron, I. Olivotto, G. Assienza, S. Hong, and J. Lesser, “Prognostic utility of contrast-enhanced cardiovascular magnetic resonance in hypertrophic cardiomyopathy: an international multicenter study,” Journal of the American College of Cardiology, vol. 59, no. 13, p. E1570, 2012. View at Publisher · View at Google Scholar
  68. L. Faber, C. Prinz, D. Welge et al., “Peak systolic longitudinal strain of the lateral left ventricular wall improves after septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: a follow-up study using speckle tracking echocardiography,” International Journal of Cardiovascular Imaging, vol. 27, no. 3, pp. 325–333, 2011. View at Publisher · View at Google Scholar · View at Scopus
  69. W. Mazur, S. F. Nagueh, N. M. Lakkis et al., “Regression of left ventricular hypertrophy after nonsurgical septal reduction therapy for hypertrophic obstructive cardiomyopathy,” Circulation, vol. 103, no. 11, pp. 1492–1496, 2001. View at Google Scholar · View at Scopus
  70. Z. Dimitriadis, F. van Buuren, N. Bogunovic, D. Horstkotte, and L. Faber, “Marked regression of left ventricular hypertrophy after outflow desobliteration in HOCM,” Case Reports in Medicine, vol. 2012, Article ID 546942, 2 pages, 2012. View at Publisher · View at Google Scholar
  71. A. Pelliccia, R. Fagard, H. H. Bjørnstad et al., “Recommendations for competitive sports participation in athletes with cardiovascular disease: a consensus document from the Study Group of Sports Cardiology of the Working Group of Cardiac Rehabilitation and Exercise Physiology and the Working Group of Myocardial and Pericardial Diseases of the European Society of Cardiology,” European Heart Journal, vol. 26, no. 14, pp. 1422–1445, 2005. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Paz, R. Jortner, P. A. Tunick et al., “The effect of the ingestion of ethanol on obstruction of the left ventricular outflow tract in hypertrophic cardiomyopathy,” The New England Journal of Medicine, vol. 335, no. 13, pp. 938–941, 1996. View at Publisher · View at Google Scholar · View at Scopus
  73. P. Spirito, C. Rapezzi, P. Bellone et al., “Infective endocarditis in hypertrophic cardiomyopathy: prevalence, incidence, and indications for antibiotic prophylaxis,” Circulation, vol. 99, no. 16, pp. 2132–2137, 1999. View at Google Scholar · View at Scopus
  74. B. J. Maron, W.-K. Shen, M. S. Link et al., “Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy,” The New England Journal of Medicine, vol. 342, no. 6, pp. 365–373, 2000. View at Publisher · View at Google Scholar · View at Scopus
  75. B. J. Maron, P. Spirito, W.-K. Shen et al., “Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy,” Journal of the American Medical Association, vol. 298, no. 4, pp. 405–412, 2007. View at Google Scholar · View at Scopus
  76. B. J. Maron, M. S. Maron, J. R. Lesser et al., “Sudden cardiac arrest in hypertrophic cardiomyopathy in the absence of conventional criteria for high risk status,” American Journal of Cardiology, vol. 101, no. 4, pp. 544–547, 2008. View at Publisher · View at Google Scholar · View at Scopus
  77. B. J. Maron, C. Semsarian, W.-K. Shen et al., “Circadian patterns in the occurrence of malignant ventricular tachyarrhythmias triggering defibrillator interventions in patients with hypertrophic cardiomyopathy,” Heart Rhythm, vol. 6, no. 5, pp. 599–602, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. P. Spirito, C. Autore, C. Rapezzi et al., “Syncope and risk of sudden death in hypertrophic cardiomyopathy,” Circulation, vol. 119, no. 13, pp. 1703–1710, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. B. J. Maron, T. S. Haas, K. M. Shannon, A. K. Almquist, and J. S. Hodges, “Long-term survival after cardiac arrest in hypertrophic cardiomyopathy,” Heart Rhythm, vol. 6, no. 7, pp. 993–997, 2009. View at Publisher · View at Google Scholar · View at Scopus
  80. B. J. Maron and P. Spirito, “Implantable defibrillators and prevention of sudden death in hypertrophic cardiomyopathy,” Journal of Cardiovascular Electrophysiology, vol. 19, no. 10, pp. 1118–1126, 2008. View at Publisher · View at Google Scholar · View at Scopus
  81. L. Monserrat, P. M. Elliott, J. R. Gimeno, S. Sharma, M. Penas-Lado, and W. J. McKenna, “Non-sustained ventricular tachycardia in hypertrophic cardiomyopathy: an independent marker of sudden death risk in young patients,” Journal of the American College of Cardiology, vol. 42, no. 5, pp. 873–879, 2003. View at Publisher · View at Google Scholar · View at Scopus
  82. A. S. Adabag, B. J. Maron, E. Appelbaum et al., “Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance,” Journal of the American College of Cardiology, vol. 51, no. 14, pp. 1369–1374, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. P. Melacini, B. J. Maron, F. Bobbo et al., “Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic cardiomyopathy,” Heart, vol. 93, no. 6, pp. 708–710, 2007. View at Publisher · View at Google Scholar · View at Scopus
  84. M. V. Sherrid, I. Barac, W. J. McKenna et al., “Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 45, no. 8, pp. 1251–1258, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. S. Nistri, I. Olivotto, M. S. Maron et al., “β blockers for prevention of exercise-induced left ventricular outflow tract obstruction in patients with hypertrophic cardiomyopathy,” American Journal of Cardiology, vol. 110, no. 5, pp. 715–719, 2012. View at Publisher · View at Google Scholar
  86. Y. J. Shimada, J. J. Passeri, A. L. Baggish et al., “Effects of losartan on left ventricular hypertrophy and fibrosis in patients with nonobstructive hypertrophic cardiomyopathy,” Journal of the American College of Cardiology: Heart Failure, vol. 1, pp. 480–487, 2013. View at Google Scholar
  87. B. Heric, B. W. Lytle, D. P. Miller et al., “Surgical management of hypertrophic obstructive cardiomyopathy: early and late results,” Journal of Thoracic and Cardiovascular Surgery, vol. 110, no. 1, pp. 195–208, 1995. View at Publisher · View at Google Scholar · View at Scopus
  88. R. C. Robbins, E. B. Stinson, and P. O. Daily, “Long-term results of left ventricular myotomy and myectomy for obstructive hypertrophic cardiomyopathy,” Journal of Thoracic and Cardiovascular Surgery, vol. 111, no. 3, pp. 586–594, 1996. View at Publisher · View at Google Scholar · View at Scopus
  89. H. D. Schulte, H. Gramsch-Zabel, and B. Schwartzkopff, “Hypertrophische obstruktive Kardiomyopathie: chirurgische Behandlung,” Schweizerische Medizinische Wochenschrift, vol. 125, pp. 1940–1949, 1995. View at Google Scholar
  90. H. D. Schulte, W. Bircks, and B. Lösse, “Techniques and complications of transaortic subvalvular myectomy in patients with hypertrophic obstructive cardiomyopathy (HOCM),” Zeitschrift fur Kardiologie, vol. 76, no. 3, pp. 145–151, 1987. View at Google Scholar · View at Scopus
  91. A. G. Morrow, B. A. Reitz, S. E. Epstein et al., “Operative treatment in hypertrophic subaortic stenosis. Techniques, and the results of pre and postoperative assessments in 83 patients,” Circulation, vol. 52, no. 1, pp. 88–102, 1975. View at Google Scholar · View at Scopus
  92. R. B. McCully, R. A. Nishimura, A. J. Tajik, H. V. Schaff, and G. K. Danielson, “Extent of clinical improvement after surgical treatment of hypertrophic obstructive cardiomyopathy,” Circulation, vol. 94, no. 3, pp. 467–471, 1996. View at Google Scholar · View at Scopus
  93. N. G. Smedira, B. W. Lytle, H. M. Lever et al., “Current effectiveness and risks of isolated septal myectomy for hypertrophic obstructive cardiomyopathy,” Annals of Thoracic Surgery, vol. 85, no. 1, pp. 127–133, 2008. View at Publisher · View at Google Scholar · View at Scopus
  94. S. R. Ommen, B. J. Maron, I. Olivotto et al., “Long-term effects of surgical septal myectomy on survival in patients with obstructive hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 46, no. 3, pp. 470–476, 2005. View at Publisher · View at Google Scholar · View at Scopus
  95. A. G. Morrow and E. C. Brockenbrough, “Surgical treatment of idiopathic hypertrophic subaortic stenosis: technic and hemodynamic results of subaortic ventriculomyotomy,” Annals of Surgery, vol. 154, pp. 181–189, 1961. View at Google Scholar · View at Scopus
  96. A. Woo, W. G. Williams, R. Choi et al., “Clinical and echocardiographic determinants of long-term survival after surgical myectomy in obstructive hypertrophic cardiomyopathy,” Circulation, vol. 111, no. 16, pp. 2033–2041, 2005. View at Publisher · View at Google Scholar · View at Scopus
  97. W. Ball, J. Ivanov, H. Rakowski et al., “Long-term survival in patients with resting obstructive hypertrophic cardiomyopathy: comparison of conservative versus invasive treatment,” Journal of the American College of Cardiology, vol. 58, no. 22, pp. 2313–2321, 2011. View at Publisher · View at Google Scholar · View at Scopus
  98. B. J. Maron, R. A. Nishimura, W. J. McKenna, H. Rakowski, M. E. Josephson, and R. S. Kieval, “Assessment of permanent dual-chamber pacing as a treatment for drug- refractory symptomatic patients with obstructive hypertrophic cardiomyopathy: a randomized, double-blind, crossover study (M-PATHY),” Circulation, vol. 99, no. 22, pp. 2927–2933, 1999. View at Google Scholar · View at Scopus
  99. U. Sigwart, “Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy,” The Lancet, vol. 346, no. 8969, pp. 211–214, 1995. View at Google Scholar · View at Scopus
  100. U. Sigwart, M. Grbic, J. J. Goy et al., “Left ventricular function after revascularization for coronary occlusion lasting 1-2 hours,” Schweizerische Medizinische Wochenschrift, vol. 113, no. 45, pp. 1661–1664, 1983. View at Google Scholar · View at Scopus
  101. P. Brugada, H. De Swart, J. L. R. M. Smeets, and H. J. J. Wellens, “Transcoronary chemical ablation of ventricular tachycardia,” Circulation, vol. 79, no. 3, pp. 475–82, 1989. View at Google Scholar · View at Scopus
  102. F. Gietzen, C. Leuner, T. Gerenkamp, and H. Kuhn, “Relief of obstruction in hypertrophic cardiomyopathy by transient occlusion of the first septal branch of the left coronary artery,” European Heart Journal, vol. 15, pp. 125–126, 1994. View at Publisher · View at Google Scholar
  103. H. Kuhn, F. Gietzen, C. Leuner, and T. Gerenkamp, “Induction of subaortic septal ischaemia to reduce obstruction in hypertrophic obstructive cardiomyopathy,” European Heart Journal, vol. 18, no. 5, pp. 846–851, 1997. View at Google Scholar · View at Scopus
  104. G. Berghöfer, Einfluß der Septumperfusion auf die Obstruktion der linksventrikulären Ausflußbahn bei HOCM (personal communication in 1998), 1989.
  105. E. Braunwald, “Induced septal infarction: a new therapeutic strategy for hypertrophic obstructive cardiomyopathy,” Circulation, vol. 95, no. 8, pp. 1981–1982, 1997. View at Google Scholar · View at Scopus
  106. P. Boekstegers, P. Steinbigler, A. Molnar et al., “Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy,” Journal of the American College of Cardiology, vol. 38, no. 3, pp. 846–853, 2001. View at Publisher · View at Google Scholar · View at Scopus
  107. S. M. Chang, N. M. Lakkis, J. Franklin, W. H. Spencer III, and S. F. Nagueh, “Predictors of outcome after alcohol septal ablation therapy in patients with hypertrophic obstructive cardiomyopathy,” Circulation, vol. 109, no. 7, pp. 824–827, 2004. View at Publisher · View at Google Scholar · View at Scopus
  108. L. Faber, H. Seggewiss, and U. Gleichmann, “Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: results with respect to intraprocedural myocardial contrast echocardiography,” Circulation, vol. 98, no. 22, pp. 2415–2421, 1998. View at Google Scholar · View at Scopus
  109. L. Faber, P. Ziemssen, and H. Seggewiss, “Targeting percutaneous transluminal septal ablation for hypertrophic obstructive cardiomyopathy by intraprocedural echocardiographic monitoring,” Journal of the American Society of Echocardiography, vol. 13, no. 12, pp. 1074–1079, 2000. View at Google Scholar · View at Scopus
  110. L. Faber, A. Meissner, P. Ziemssen, and H. Seggewiss, “Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients,” Heart, vol. 83, no. 3, pp. 326–331, 2000. View at Google Scholar · View at Scopus
  111. R. Flores-Ramirez, N. M. Lakkis, K. J. Middleton, D. Killip, W. H. Spencer III, and S. F. Nagueh, “Echocardiographic insights into the mechanisms of relief of left ventricular outflow tract obstruction after nonsurgical septal reduction therapy in patients with hypertrophic obstructive cardiomyopathy,” Journal of the American College of Cardiology, vol. 37, no. 1, pp. 208–214, 2001. View at Publisher · View at Google Scholar · View at Scopus
  112. F. H. Gietzen, C. J. Leuner, U. Raute-Kreinsen et al., “Acute and long-term results after transcoronary ablation of septal hypertrophy (TASH),” European Heart Journal, vol. 20, no. 18, pp. 1342–1354, 1999. View at Publisher · View at Google Scholar · View at Scopus
  113. C. Knight, A. S. Kurbaan, H. Seggewiss et al., “Nonsurgical septal reduction for hypertrophic obstructive cardiomyopathy: outcome in the first series of patients,” Circulation, vol. 95, no. 8, pp. 2075–2081, 1997. View at Google Scholar · View at Scopus
  114. H. Kuhn, H. Seggewiss, F. H. Gietzen, P. Boekstegers, L. Neuhaus, and L. Seipel, “Catheter-based therapy for hypertrophic obstructive cardiomyopathy: first in-hospital outcome analysis of the German TASH Registry,” Zeitschrift fur Kardiologie, vol. 93, no. 1, pp. 23–31, 2004. View at Publisher · View at Google Scholar · View at Scopus
  115. L. Faber, H. Seggewiss, F. H. Gietzen et al., “Catheter-based septalablation for symptomatic hypertrophic obstructive cardiomyopathy: follow-up results of the TASH-registry of the German Cardiac Society,” Zeitschrift fur Kardiologie, vol. 94, no. 8, pp. 516–523, 2005. View at Publisher · View at Google Scholar · View at Scopus
  116. N. M. Lakkis, S. F. Nagueh, N. S. Kleiman et al., “Echocardiography-guided ethanol septal reduction for hypertrophic obstructive cardiomyopathy,” Circulation, vol. 98, no. 17, pp. 1750–1755, 1998. View at Google Scholar · View at Scopus
  117. J. X. Qin, T. Shiota, H. M. Lever et al., “Conduction system abnormalities in patients with obstructive hypertrophic cardiomyopathy following septal reduction interventions,” American Journal of Cardiology, vol. 93, no. 2, pp. 171–175, 2004. View at Publisher · View at Google Scholar · View at Scopus
  118. J. Xin, T. Shiota, H. M. Lever et al., “Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery,” Journal of the American College of Cardiology, vol. 38, no. 7, pp. 1994–2000, 2001. View at Publisher · View at Google Scholar · View at Scopus
  119. H. Seggewiss, U. Gleichmann, L. Faber, D. Fassbender, H. K. Schmidt, and S. Strick, “Percutaneous transluminal septal myocardial ablation in hypertrophic obstructive cardiomyopathy: acute results and 3-month follow-up in 25 patients,” Journal of the American College of Cardiology, vol. 31, no. 2, pp. 252–258, 1998. View at Publisher · View at Google Scholar · View at Scopus
  120. H. Seggewiss, “Current status of alcohol septal ablation for patients with hypertrophic cardiomyopathy,” Current Cardiology Reports, vol. 3, no. 2, pp. 160–166, 2001. View at Google Scholar · View at Scopus
  121. U. S. Valeti, R. A. Nishimura, D. R. Holmes et al., “Comparison of surgical septal myectomy and alcohol septal ablation with cardiac magnetic resonance imaging in patients with hypertrophic obstructive cardiomyopathy,” Journal of the American College of Cardiology, vol. 49, no. 3, pp. 350–357, 2007. View at Publisher · View at Google Scholar · View at Scopus
  122. S. Agarwal, E. M. Tuzcu, M. Y. Desai et al., “Updated meta-analysis of septal alcohol ablation versus myectomy for hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 55, no. 8, pp. 823–834, 2010. View at Publisher · View at Google Scholar · View at Scopus
  123. P. A. Noseworthy, M. A. Rosenberg, M. A. Fifer et al., “Ventricular arrhythmia following alcohol septal ablation for obstructive hypertrophic cardiomyopathy,” American Journal of Cardiology, vol. 104, no. 1, pp. 128–132, 2009. View at Publisher · View at Google Scholar · View at Scopus
  124. S. Firoozi, P. M. Elliott, S. Sharma et al., “Septal myotomy-myectomy and transcoronary septal alcohol ablation in hypertrophic obstructive cardiomyopathy: a comparison of clinical, haemodynamic and exercise outcomes,” European Heart Journal, vol. 23, no. 20, pp. 1617–1624, 2002. View at Publisher · View at Google Scholar · View at Scopus
  125. P. Sorajja, U. Valeti, R. A. Nishimura et al., “Outcome of alcohol septal ablation for obstructive hypertrophic cardiomyopathy,” Circulation, vol. 118, no. 2, pp. 131–139, 2008. View at Publisher · View at Google Scholar · View at Scopus
  126. F. A. Cuoco, W. H. Spencer III, V. L. Fernandes et al., “Implantable cardioverter-defibrillator therapy for primary prevention of sudden death after alcohol septal ablation of hypertrophic cardiomyopathy,” Journal of the American College of Cardiology, vol. 52, no. 21, pp. 1718–1723, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. S. F. Nagueh, B. M. Groves, L. Schwartz et al., “Alcohol septal ablation for the treatment of hypertrophic obstructive cardiomyopathy: a multicenter north american registry,” Journal of the American College of Cardiology, vol. 58, no. 22, pp. 2322–2328, 2011. View at Publisher · View at Google Scholar · View at Scopus
  128. C. Prinz, J. Vogt, B. G. Muntean, D. Hering, D. Horstkotte, and L. Faber, “Incidence of adequate ICD interventions in patients with hypertrophic cardiomyopathy supposed to be at high risk for sudden cardiac death,” Acta Cardiologica, vol. 65, no. 5, pp. 521–525, 2010. View at Publisher · View at Google Scholar · View at Scopus
  129. L. Faber, D. Welge, D. Hering et al., “Percutaneous septal ablation after unsuccessful surgical myectomy for patients with hypertrophic obstructive cardiomyopathy,” Clinical Research in Cardiology, vol. 97, no. 12, pp. 899–905, 2008. View at Publisher · View at Google Scholar · View at Scopus
  130. L. Faber, D. Welge, D. Fassbender, H. K. Schmidt, D. Horstkotte, and H. Seggewiss, “One-year follow-up of percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy in 312 patients: predictors of hemodynamic and clinical response,” Clinical Research in Cardiology, vol. 96, no. 12, pp. 864–873, 2007. View at Publisher · View at Google Scholar · View at Scopus
  131. M. K. Jensen, C. Prinz, D. Horstkotte et al., “Alcohol septal ablation in patients with hypertrophic obstructive cardiomyopathy: low incidence of sudden cardiac death and reduced risk profile,” Heart, vol. 99, pp. 1012–1017, 2013. View at Google Scholar
  132. M. Alam, H. Dokainish, and N. Lakkis, “Alcohol septal ablation for hypertrophic obstructive cardiomyopathy: a systematic review of published studies,” Journal of Interventional Cardiology, vol. 19, no. 4, pp. 319–327, 2006. View at Publisher · View at Google Scholar · View at Scopus
  133. V. L. Fernandes, C. Nielsen, S. F. Nagueh et al., “Follow-Up of Alcohol Septal Ablation for Symptomatic Hypertrophic Obstructive Cardiomyopathy. The Baylor and Medical University of South Carolina Experience 1996 to 2007,” JACC: Cardiovascular Interventions, vol. 1, no. 5, pp. 561–570, 2008. View at Publisher · View at Google Scholar · View at Scopus
  134. P. Sorajja, S. R. Ommen, D. R. Holmes Jr et al., “Survival after alcohol septal ablation for obstructive hypertrophic cardiomyopathy,” Circulation, vol. 126, pp. 2374–2380, 2012. View at Publisher · View at Google Scholar
  135. A. A. Chen, I. F. Palacios, T. Mela et al., “Acute predictors of subacute complete heart block after alcohol septal ablation for obstructive hypertrophic cardiomyopathy,” American Journal of Cardiology, vol. 97, no. 2, pp. 264–269, 2006. View at Publisher · View at Google Scholar · View at Scopus
  136. T. Lawrenz, F. Lieder, M. Bartelsmeier et al., “Predictors of complete heart block after transcoronary ablation of septal hypertrophy: results of a prospective electrophysiological investigation in 172 patients with hypertrophic obstructive cardiomyopathy,” Journal of the American College of Cardiology, vol. 49, no. 24, pp. 2356–2363, 2007. View at Publisher · View at Google Scholar · View at Scopus
  137. F. J. Ten Cate, O. I. I. Soliman, M. Michels et al., “Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution,” Circulation: Heart Failure, vol. 3, no. 3, pp. 362–369, 2010. View at Publisher · View at Google Scholar · View at Scopus
  138. M. A. Fifer, “Most fully informed patients choose septal ablation over septal myectomy,” Circulation, vol. 116, no. 2, pp. 207–216, 2007. View at Publisher · View at Google Scholar · View at Scopus
  139. T. Lawrenz, B. Borchert, C. Leuner et al., “Endocardial radiofrequency ablation for hypertrophic obstructive cardiomyopathy: acute results and 6 months' follow-up in 19 patients,” Journal of the American College of Cardiology, vol. 57, no. 5, pp. 572–576, 2011. View at Publisher · View at Google Scholar · View at Scopus
  140. A. Oto, K. Aytemir, S. Okutucu et al., “Cyanoacrylate for septal ablation in hypertrophic cardiomyopathy,” Journal of Interventional Cardiology, vol. 24, no. 1, pp. 77–84, 2011. View at Publisher · View at Google Scholar · View at Scopus